24/7 Market News Snapshot 07 October, 2025 – Soligenix, Inc. Common Stock (NASDAQ:SNGX)
DENVER, Colo., 07 October, 2025 (www.247marketnews.com) – (NASDAQ:SNGX) are discussed in this article.
Soligenix, Inc. has seen a significant uptick in pre-market trading, with shares rising 17.96% to $1.616, up from the previous close of $1.370. This bullish trend is indicative of strong investor sentiment, likely fueled by the company’s recent developments. Current trading volume has reached 2.28 million, suggesting increased market engagement and potential momentum for Soligenix. To sustain this upward trajectory, the company must maintain its share price above the key support level of $1.370, with the next resistance target around $1.700. Investors are encouraged to closely watch for additional news and trading volume shifts, as these factors can greatly influence market dynamics.
In conjunction with its stock market performance, Soligenix has achieved a critical milestone in its clinical development pipeline. The company successfully completed the first Data Monitoring Committee (DMC) meeting for its confirmatory Phase 3 study of HyBryte™ (synthetic hypericin), aimed at treating cutaneous T-cell lymphoma (CTCL). The DMC confirmed an acceptable safety profile consistent with prior studies, allowing the FLASH2 study to advance without concerns.
Dr. Christopher J. Schaber, President and CEO of Soligenix, expressed enthusiasm about the ongoing patient enrollment, which is on track, and anticipates updates regarding enrollment numbers and an interim efficacy analysis anticipated in the first half of 2026. The FLASH2 study is a randomized, double-blind trial that builds upon a previous successful study, extending treatment duration to 18 weeks. Dr. Ellen Kim, the Lead Investigator, highlighted the urgency for alternative CTCL treatments, positioning HyBryte™ as a promising option that could potentially enhance patient outcomes. As the trial progresses, Soligenix is focused on advancing regulatory approvals that may support the global commercialization of HyBryte™.